作者用随机、双盲、多中心试验,研究了口服两种剂量美塞拉明(Mesalamine)治疗轻度和中度溃疡性结肠炎的疗效和安全性。对象和方法随机抽选患者158例作为疗效观察对象。年龄18～75岁,均在近24月内经结肠镜或直、乙状镜和钡剂灌肠诊断有轻到中度活动性溃疡性结肠炎。伴有肾、肝功能障碍,近1月内用过类固醇类药物和对 In a randomized, double-blind, multicentre trial, we investigated the efficacy and safety of oral doses of Mesalamine in the treatment of mild and moderate ulcerative colitis. Subjects and methods A random sample of 158 patients as the efficacy of observation. Aged 18 to 75 years old, were diagnosed with mild to moderate active ulcerative colitis by colonoscopy or straight, sigmoidoscopy and barium enema in nearly 24 months. Accompanied by kidney, liver dysfunction, steroids and drugs used in the past January